VBI Vaccines Announces Second Pivotal Phase 3 Study of Sci-B-Vac® Meets Primary and Secondary Endpoints
VBI Vaccines, Inc. - Ordinary Shares (VBIV)
Last vbi vaccines, inc. - ordinary shares earnings: 11/6 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
vbivaccines.com/investors
Company Research
Source: Business Wire
Lot-to-lot manufacturing consistency of Sci-B-Vac®, the primary endpoint, was demonstratedSci-B-Vac® achieved seroprotection rates of 99.3% and 90.4% after three and two doses, respectively, compared with 94.8% and 51.6% with Engerix-B®, respectivelyNo safety signals observed – safety profile remains consistent with known profile of the vaccineRegulatory submissions in U.S., Europe, and Canada expected to begin in the second half of 2020VBI to host conference call and webcast today, Thursday, January 9, 2020 at 8:30AM ET CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today reported top-line data from CONSTANT, the second pivotal Phase 3 study, assessing lot-to-lot manufacturing consistency of Sci-B-Vac®, the company’s trivalent hepatitis B (HBV) vaccine, and comparing safety and immunogenicity of Sci-B-Vac® to GlaxoSmithKline’s curren
Show less
Read more
Impact Snapshot
Event Time:
VBIV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VBIV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VBIV alerts
High impacting VBI Vaccines, Inc. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
VBIV
News
- BRII-835 + BRII-179 for Chronic Hepatitis B in 7MM: Market Size, Forecast, and Emerging Insights 2019-2032 [Yahoo! Finance]Yahoo! Finance
- VBI Vaccines Inc. (NASDAQ: VBIV) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- VBI Vaccines Reports Full Year 2023 Financial Results [Yahoo! Finance]Yahoo! Finance
- VBI Vaccines Reports Full Year 2023 Financial ResultsBusiness Wire
- VBI Vaccines Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules [Yahoo! Finance]Yahoo! Finance
VBIV
Earnings
- 11/14/23 - Miss
VBIV
Sec Filings
- 4/17/24 - Form SC
- 4/16/24 - Form 10-K
- 4/16/24 - Form 8-K
- VBIV's page on the SEC website